logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12215362 B1

PDFFull Text
Date of Patent:
Feb. 04, 2025

Filed:

Sep. 28, 2018

Pharmaceutical composition for prevention or treatment of heart failure

Applicant:

Bethphagen Inc., Gwangju, KR;

Inventors:

Tae Hwan Kwak, Yongin-si, KR;

Woo Jin Park, Gwangju, KR;

Assignee:

BETHPHAGEN INC., Gwangju, KR;

Attorney:

Sughrue Mion, PLLC

Primary Examiner:

Neil P Hammell

Assistant Examiner:

Khaleda B Hasan

Int. Cl.
CPC ...
A61P 9/00 (2006.01); A61K 35/76 (2015.01); A61K 38/17 (2006.01); A61K 48/00 (2006.01); C07K 14/47 (2006.01); C12N 7/00 (2006.01); C12N 9/14 (2006.01); C12N 15/85 (2006.01); C12N 15/86 (2006.01); G01N 33/68 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/14 (2013.01); A61K 35/76 (2013.01); A61K 38/1738 (2013.01); A61K 38/179 (2013.01); A61K 48/0066 (2013.01); A61P 9/00 (2018.01); C07K 14/47 (2013.01); C12N 7/00 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); C12Y 306/03008 (2013.01); G01N 33/6893 (2013.01); A61K 38/00 (2013.01); A61K 48/00 (2013.01); C12N 2750/14143 (2013.01); C12N 2800/107 (2013.01); G01N 2800/325 (2013.01);
Abstract

The present invention relates to a pharmaceutical composition for prevention and treatment of heart failure. Specifically, the present invention relates to a gene construct comprising a polynucleotide coding for SERCA2a protein or a fragment thereof and a polynucleotide coding for CCN5 protein or a fragment thereof, and a pharmaceutical composition comprising the same construct as an effective ingredient for preventing or treating heart failure. A pharmaceutical composition for prevention and treatment of heart failure according to the present invention is used in a method for co-expression of SERCA2a protein and CCN5 protein. Designed to exert a synergistic therapeutic effect through SERCA2a protein's function of preventing the loss of cardiomyocytes and increasing the activity of cardiomyocytes and CCN5 protein's function of suppressing the fibrosis of heart cells and tissues, the pharmaceutical composition can be useful for preventing or treating heart failure, which is a complex disorder induced by various etiological factors.

Find Patent Forward Citations

Loading…